Serum Institute of India

India’s first indigenously developed qHPV against cervical cancer

Recently Serum Institute of India (SII) and Department of Biotechnology (DBT) launched indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for prevention of cervical cancer. Highlights The Drug Controller General of India (DCGI) last month granted market authorization to Serum ..



IndRa: Cost of vaccinating India’s population above 18 years 0.36% of GDP

The India Ratings and Research (Ind-Ra) recently said the estimated cost to vaccinate all the Indians of age 18 years will be Rs 67,193 crores. This is 0.36% of the GDP of the country. Key Findings The GoI recently announced ..


PM Takes First Dose of COVID-19 Vaccine

The Prime Minister of India, Narendra Modi, takes first dose of COVID-19 vaccine on March 1, 2021 at AIIMS, New Delhi. After vaccination, he appealed to those people who are eligible to get their vaccination done. Covid-19 Vaccination in India ..


COVID-19 Vaccination Phase 2 to begin from March 1

The Union Government has announced that the second phase of COVID-19 vaccination will begin from March 1, 2021. Highlights Under the second phase of covid-19 vaccination, people aged above 60 years will get vaccinated. Further, as per the guidelines, those ..


SII’s Covishield gets emergency-use nod from DGCI

The Subject Expert committee that is advising the Drug Controller General of India (DCGI) recommended restricted Emergency Use Authorisation for COVISHIELD. COVISHIELD vaccine was developed by Serum Institute of India. Who manufactures COVISHIELD? The COVISHIELD the vaccine is developed by ..


Pneumosil: India’s First Pneumonia Vaccine

The Serum Institute of India recently unveiled the first indigenously developed Pneumococcal Vaccine called Pneumosil. The vaccine was launched by the Union Health Minister Harsh Vardhan. About the Vaccine Pneumosil was developed through collaboration with Bill and Melinda Gates Foundation ..